Literature DB >> 21820294

Volumetric modulated arc therapy with simultaneous integrated boost for locally advanced rectal cancer.

S Cilla1, L Caravatta, V Picardi, D Sabatino, G Macchia, C Digesù, F Deodato, M Massaccesi, M De Spirito, A Piermattei, A G Morganti.   

Abstract

AIMS: To report the feasibility of volumetric modulated arc therapy (VMAT) for neoadjuvant radiotherapy in locally advanced rectal cancer in a dose-escalation protocol and simultaneous integrated boost (SIB) approach. Moreover, the VMAT technique was compared with three-dimensional conformal radiotherapy (3D-CRT) and fixed-field intensity modulated radiotherapy (IMRT), in terms of target coverage and irradiation of organs at risk.
MATERIALS AND METHODS: Eight patients with locally advanced rectal cancer were treated with the SIB-VMAT technique. The VMAT plans were compared with 3D-CRT and IMRT techniques in terms of several clinically dosimetric parameters. The number of monitor units and the delivery time were analysed to score the treatment efficiency. All plans were verified in a dedicated solid water phantom using a two-dimensional array of ionisation chambers.
RESULTS: All techniques meet the prescription goal for planning target volume coverage, with VMAT showing the highest level of conformality. VMAT is associated with 40, 53 and 58% reduction in the percentage of volume of small bowel irradiated to 30, 40 and 50Gy, compared with 3D-CRT. No significant differences were found with respect to SIB-IMRT. VMAT plans showed a significant reduction of monitor units by nearly 20% with respect to IMRT and reduced treatment time from 14 to 5min for a single fraction.
CONCLUSIONS: SIB-VMAT plans can be planned and carried out with high quality and efficiency for rectal cancer, providing similar sparing of organs at risk to SIB-IMRT and resulting in the most efficient treatment option. SIB-VMAT is currently our standard approach for radiotherapy of locally advanced rectal cancer.
Copyright © 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21820294     DOI: 10.1016/j.clon.2011.07.001

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  15 in total

1.  The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer.

Authors:  Lynsey Devlin; Laura Grocutt; Bianca Hunter; Hiwot Chemu; Aileen Duffton; Alec McDonald; Nicholas Macleod; Philip McLoone; Sean M O'Cathail
Journal:  Clin Transl Radiat Oncol       Date:  2022-06-11

2.  Progress in rectal cancer treatment.

Authors:  Wim P Ceelen
Journal:  ISRN Gastroenterol       Date:  2012-08-30

3.  A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer.

Authors:  Farshad Foroudi; Lesley Wilson; Mathias Bressel; Annette Haworth; Colin Hornby; Daniel Pham; Jim Cramb; Suki Gill; Keen Hun Tai; Tomas Kron
Journal:  Radiat Oncol       Date:  2012-07-23       Impact factor: 3.481

4.  Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy.

Authors:  Leif Hendrik Dröge; Hanne Elisabeth Weber; Manuel Guhlich; Martin Leu; Lena-Christin Conradi; Jochen Gaedcke; Steffen Hennies; Markus Karl Herrmann; Margret Rave-Fränk; Hendrik Andreas Wolff
Journal:  BMC Cancer       Date:  2015-10-20       Impact factor: 4.430

5.  VMAT planning study in rectal cancer patients.

Authors:  Jun Shang; Wei Kong; Yan-yang Wang; Zhe Ding; Gang Yan; Hong Zhe
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481

6.  Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.

Authors:  Chia-Chun Wang; Jin-Tung Liang; Chiao-Ling Tsai; Yu-Hsuan Chen; Yu-Lin Lin; Chia-Tung Shun; Jason Chia-Hsien Cheng
Journal:  World J Surg Oncol       Date:  2014-11-06       Impact factor: 2.754

7.  Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost.

Authors:  Jun Zhao; Weigang Hu; Gang Cai; Jiazhou Wang; Jiang Xie; Jiayuan Peng; Zhen Zhang
Journal:  Oncotarget       Date:  2016-02-02

8.  Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy.

Authors:  Lin Xiao; Xin Yu; Wenjing Deng; Huixia Feng; Hui Chang; Weiwei Xiao; Huizhong Zhang; Shaoyan Xi; Mengzhong Liu; Yujia Zhu; Yuanhong Gao
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

9.  The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes In Rectal Cancer.

Authors:  Lara Hathout; Terence M Williams; Salma K Jabbour
Journal:  Curr Colorectal Cancer Rep       Date:  2017-03-10

10.  Comparative Analysis of Efficacy, Toxicity, and Patient-Reported Outcomes in Rectal Cancer Patients Undergoing Preoperative 3D Conformal Radiotherapy or VMAT.

Authors:  Antonia Regnier; Jana Ulbrich; Stefan Münch; Markus Oechsner; Dirk Wilhelm; Stephanie E Combs; Daniel Habermehl
Journal:  Front Oncol       Date:  2017-09-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.